Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis

Article English OPEN
Silvia Aldi; Ljubica Perisic Matic; Gregory Hamm; Daniëlle van Keulen; Dennie Tempel; Kim Holmstrøm; Agnieszka Szwajda; Boye Schnack Nielsen; Valur Emilsson; Rima Ait-Belkacem; Mariette Lengquist; Gabrielle Paulsson-Berne; Per Eriksson; Jan H.N. Lindeman; Alain J. Gool; Jonathan Stauber; Ulf Hedin; Eva Hurt-Camejo; (2018)
  • Publisher: Elsevier
  • Journal: Molecular Therapy: Methods & Clinical Development,volume 10,pages17-28 (issn: 2329-0501, eissn: 2329-0501)
  • Related identifiers: doi: 10.1016/j.omtm.2018.05.003, pmc: PMC6039967
  • Subject: atherosclerosis | Cytology | QH426-470 | Genetics | therapy | QH573-671 | biobank profiling | Article
    mesheuropmc: lipids (amino acids, peptides, and proteins)

Variants in the PLPP3 gene encoding for lipid phosphate phosphohydrolase 3 have been associated with susceptibility to atherosclerosis independently of classical risk factors. PLPP3 inactivates lysophosphatidic acid (LPA), a pro-inflammatory, pro-thrombotic product of p... View more
Share - Bookmark